What is Chardan Capital's Estimate for LXEO FY2025 Earnings?

Key Points

• Chardan Capital has increased its FY2025 earnings per share forecast for Lexeo Therapeutics from ($2.98) to ($1.99), maintaining a "Buy" rating with a target price of $15.00.
• Lexeo Therapeutics reported earnings of ($0.60) per share in its last quarterly announcement, exceeding projections of ($0.64).
• Despite varying price targets from different analysts, the average consensus rating for Lexeo Therapeutics remains a "Buy" with an estimated price target of $15.33.

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Equities research analysts at Chardan Capital raised their FY2025 earnings estimates for shares of Lexeo Therapeutics in a report issued on Monday, August 18th. Chardan Capital analyst G. Livshits now expects that the company will post earnings per share of ($1.99) for the year, up from their prior estimate of ($2.98). Chardan Capital currently has a "Buy" rating and a $15.00 target price on the stock. The consensus estimate for Lexeo Therapeutics' current full-year earnings is ($3.14) per share.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.60) EPS for the quarter, topping analysts' consensus estimates of ($0.64) by $0.04.

LXEO has been the subject of a number of other reports. Oppenheimer initiated coverage on shares of Lexeo Therapeutics in a report on Thursday, July 31st. They set an "outperform" rating and a $20.00 price objective for the company. HC Wainwright reduced their price objective on shares of Lexeo Therapeutics from $15.00 to $9.00 and set a "buy" rating for the company in a report on Friday, August 15th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Lexeo Therapeutics from $16.00 to $10.00 and set an "overweight" rating for the company in a report on Friday, May 30th. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Lexeo Therapeutics presently has an average rating of "Buy" and an average price target of $15.33.

Lexeo Therapeutics Stock Performance

Shares of NASDAQ:LXEO traded up $0.15 during midday trading on Thursday, reaching $4.81. 120,494 shares of the company's stock were exchanged, compared to its average volume of 638,642. The company's 50 day simple moving average is $4.39 and its two-hundred day simple moving average is $3.65. The firm has a market capitalization of $259.74 million, a PE ratio of -1.48 and a beta of 1.36. Lexeo Therapeutics has a 12 month low of $1.45 and a 12 month high of $11.96.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Millennium Management LLC boosted its stake in shares of Lexeo Therapeutics by 282.5% in the 4th quarter. Millennium Management LLC now owns 141,951 shares of the company's stock valued at $934,000 after purchasing an additional 104,837 shares during the last quarter. Marshall Wace LLP bought a new position in shares of Lexeo Therapeutics in the 4th quarter valued at about $117,000. BNP Paribas Financial Markets boosted its stake in shares of Lexeo Therapeutics by 523.1% in the 4th quarter. BNP Paribas Financial Markets now owns 34,527 shares of the company's stock valued at $227,000 after purchasing an additional 28,986 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Lexeo Therapeutics by 48.3% in the 4th quarter. Wellington Management Group LLP now owns 76,981 shares of the company's stock valued at $507,000 after purchasing an additional 25,089 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of Lexeo Therapeutics by 30.1% in the 4th quarter. JPMorgan Chase & Co. now owns 13,371 shares of the company's stock valued at $88,000 after purchasing an additional 3,093 shares during the last quarter. Institutional investors own 60.67% of the company's stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.